Telo Genomics Corp (TSE:TELO)
:TELO
Want to see TSE:TELO full AI Analyst Report?
Top Page
Telo Genomics Corp
(TELO)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.06
▲(60.00% Upside)
Action:Reiterated
Date:06/05/26
The score is primarily constrained by weak financial performance: no revenue, ongoing losses and cash burn, and a shift to negative equity alongside higher debt. Technicals provide some support with mild upward trend and neutral-to-positive momentum, while valuation is limited by a negative P/E and no dividend yield data.
Positive Factors
Proprietary telomere technology
Proprietary measurement technology represents a durable competitive asset: IP and specialized assays can create high barriers to entry, enable differentiated clinical utility, and form the basis for licensing, partnerships, or fee-for-service lab adoption once commercialized, supporting long-term revenue potential.
Negative Factors
No revenue / persistent losses
Sustained zero revenue and recurring net losses indicate the company remains pre-commercial with no current product-market cash inflows. This fundamental lack of revenue weakens earnings visibility and means future growth depends wholly on successful commercialization or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary telomere technology
Proprietary measurement technology represents a durable competitive asset: IP and specialized assays can create high barriers to entry, enable differentiated clinical utility, and form the basis for licensing, partnerships, or fee-for-service lab adoption once commercialized, supporting long-term revenue potential.
Read all positive factors
Telo Genomics Corp (TELO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.52M
Dividend YieldN/A
Average Volume (3M)29.30K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth26.96%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.03
Shares Outstanding100,430,470
10 Day Avg. Volume22,350
30 Day Avg. Volume29,304
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)18.74
Price to Sales (P/S)0.00
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Telo Genomics Corp Business Overview & Revenue Model
Company Description
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health ...
How the Company Makes Money
null...
Telo Genomics Corp Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Jun 2022 | Sep 2020 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -54.93K | -14.45K | -39.54K | -33.11K | -62.23K | -64.72K |
| EBITDA | -2.21M | -2.69M | -2.67M | -2.78M | -1.01M | -1.15M |
| Net Income | -2.34M | -2.72M | -2.71M | -2.82M | -1.07M | -1.24M |
Balance Sheet | ||||||
| Total Assets | 1.22M | 911.30K | 965.64K | 2.93M | 3.84M | 1.17M |
| Cash, Cash Equivalents and Short-Term Investments | 975.48K | 789.29K | 796.02K | 2.67M | 3.64M | 920.98K |
| Total Debt | 1.32M | 0.00 | 0.00 | 32.50K | 40.00K | 40.00K |
| Total Liabilities | 2.19M | 396.32K | 375.59K | 312.87K | 153.66K | 393.42K |
| Stockholders Equity | -970.21K | 514.98K | 590.06K | 2.61M | 3.69M | 775.25K |
Cash Flow | ||||||
| Free Cash Flow | -1.52M | -2.33M | -2.46M | -2.70M | -1.11M | -1.13M |
| Operating Cash Flow | -1.30M | -2.33M | -2.46M | -2.63M | -1.10M | -1.12M |
| Investing Cash Flow | -224.99K | -3.25K | -5.12K | -69.06K | -9.31K | -8.67K |
| Financing Cash Flow | 1.25M | 2.33M | 587.05K | 2.68M | 3.83M | 2.03M |
Telo Genomics Corp Technical Analysis
Positive
0.04
Price Trends
0.06
Positive
0.05
Positive
0.06
Positive
Market Momentum
<0.01
Positive
54.96
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.96 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TELO.
Telo Genomics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$56.75M | -33.39 | ― | ― | -40.80% | 22.49% | |
46 Neutral | C$5.52M | -2.37 | -9999.00% | ― | ― | 26.96% | |
42 Neutral | C$5.06M | -2.55 | -95.29% | ― | -96.48% | -117.78% | |
41 Neutral | C$6.15M | -2.46 | ― | ― | ― | ― | |
41 Neutral | C$36.60M | -12.20 | -434.25% | ― | ― | 8.62% |
* Healthcare Sector Average
TSE:TELO
Telo Genomics Corp
0.06
-0.03
-31.25%
TSE:BUX
BioMark Diagnostics
0.54
0.22
68.75%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:KNE
Kane Biotech
0.03
-0.03
-50.00%
TSE:SONA
Sona Nanotech Inc
0.32
-0.08
-20.00%
TSE:AVCR
Avricore Health
0.05
0.00
0.00%
Telo Genomics Corp Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Telo Genomics Advances Blood-Based MRD Testing in Myeloma with New Study and CAP Accreditation
Positive
Apr 14, 2026
Telo Genomics Corp. has launched a retrospective clinical study with hematologists at the National and Kapodistrian University of Athens to advance next‑generation minimal residual disease risk stratification in multiple myeloma. The trial w...
Business Operations and StrategyExecutive/Board Changes
Telo Genomics Installs New CEO and Chairman as It Prepares for Pivotal Oncology Milestones
Positive
Mar 31, 2026
Telo Genomics Corp. has appointed audit committee chair John Farlinger as its new chief executive officer and chairman, succeeding founder Sabine Mai, who remains on the board. Farlinger, a seasoned public markets and technology executive, receive...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.